Literature DB >> 7987843

Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG-nitro-L-arginine.

P J Wood1, J M Sansom, S A Butler, I J Stratford, S M Cole, C Szabo, C Thiemermann, G E Adams.   

Abstract

The nitric oxide synthase inhibitor NG-nitro-L-arginine (NOARG) was examined for its ability to alter energy metabolism in three murine tumors using 31P magnetic resonance spectroscopy. NOARG (10 mg/kg, i.v.) increased the inorganic phosphate:total phosphate ratio (Pi:total) 2-3-fold in the KHT, RIF-1, and SCCVII/Ha intradermal back tumors from 30 min to 6 h after injection, but the 31P magnetic resonance spectrum from normal tissue on the mouse back was unchanged after this treatment. NOARG (10 mg/kg, i.v.) injected 30 min before X-rays increased tumor cell survival 3-5-fold in SCCVII/Ha and 50-200-fold in RIF-1, measured using an in vivo/in vitro clonogenic assay. These effects were equivalent to those obtained from clamped tumors, indicating full radiobiological hypoxia. In KHT, only a 2-fold increase in radioresistance was observed after NOARG, which was less than the response of clamped tumors. In RIF-1 tumors, NOARG induced full radiobiological hypoxia when given from 30 min to 6 h prior to X-rays, consistent with the time course for the increase in Pi:total, measured by 31P magnetic resonance spectroscopy. Pi:total after NOARG doses of 0.1-10 mg/kg, i.v., increased in a dose-dependent manner in this tumor. Increased RIF-1 tumor radioresistance was similarly dependent on NOARG dose. The combination of the bioreductive agent RB6145 (300 mg/kg, i.p.) 15 min prior to NOARG (10 mg/kg, i.v.) produced greater than 5 decades of KHT tumor cell killing at 24 h after treatment. This combination also increased Pi:total 4.5-fold over the control value at 24 h in the KHT tumor. Histological examination of tumors at this time indicated extensive necrosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7987843

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions.

Authors:  D Fukumura; F Yuan; M Endo; R K Jain
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

2.  Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours.

Authors:  M R Horsman; D J Chaplin; S A Hill; S Arnold; D Collingridge; M Radacic; P J Wood; J Overgaard
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 3.  Gasotransmitters in cancer: from pathophysiology to experimental therapy.

Authors:  Csaba Szabo
Journal:  Nat Rev Drug Discov       Date:  2015-12-18       Impact factor: 84.694

4.  Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts.

Authors:  Robert J G Cardnell; Ross B Mikkelsen
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

5.  Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma.

Authors:  S Q Shan; G L Rosner; R D Braun; J Hahn; C Pearce; M W Dewhirst
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Reduced capacity of tumour blood vessels to produce endothelium-derived relaxing factor: significance for blood flow modification.

Authors:  G M Tozer; V E Prise; K M Bell; M F Dennis; M R Stratford; D J Chaplin
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

7.  17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response.

Authors:  E C Chinje; K J Williams; B A Telfer; P J Wood; A J van der Kogel; I J Stratford
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

8.  Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.

Authors:  S A Butler; P J Wood; S Cole; C Williams; G E Adams; I J Stratford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma.

Authors:  R E Meyer; S Shan; J DeAngelo; R K Dodge; J Bonaventura; E T Ong; M W Dewhirst
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

10.  Microenvironmental adaptation of experimental tumours to chronic vs acute hypoxia.

Authors:  O Thews; T Wolloscheck; W Dillenburg; S Kraus; D K Kelleher; M A Konerding; P Vaupel
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.